Active, not recruitingPhase 2NCT06044350

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Studying Neuromyelitis Optica

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bio-Thera Solutions
Principal Investigator: Xiangjun Chen, Doctor
Huashan Hospital
Intervention: BAT4406F Injection(drug)
Enrollment: 162 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2023 – 2026

Study locations (30)

The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology, Baotou, China
Beijing Hospital, Beijing, China
China-japan friendship Hospital, Beijing, China
The first hospital of Peking University, Beijing, China
The Central South University Xiang Ya Hospital, Changsha, China
Xiangya 2nd hospital of central south university, Changsha, China
First affiliated hospital of chongqing medical university, Chongqing, China
The first affiliated hospital of Dalian Medical University, Dalian, China
First affiliated hospital of fujian medical university, Fuzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
The first hospital affiliated to sun yat-sen university, Guangzhou, China
The first People's Hospital of Guangzhou, Guangzhou, China
The third hospital affiliated to sun yat-sen university, Guangzhou, China
People's Hospital of Zhejiang province, Hangzhou, China
Anhui Provincial Hospital, Hefei, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06044350 on ClinicalTrials.gov

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

See all trials for Neuromyelitis Optica →

← Back to all trials